{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "18",
                "@timestamp": "2023-01-18T05:34:17.000017-05:00",
                "@year": "2023",
                "@month": "01"
            },
            "ait:date-sort": {
                "@day": "23",
                "@year": "2019",
                "@month": "07"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {"xocs:funding-agency-matched-string": "Andrew Kambugu, Infectious Diseases Institute"},
                {"xocs:funding-agency-matched-string": "Bamrasnaradura Infectious Disease Institute"},
                {"xocs:funding-agency-matched-string": "Helen Joseph Hospital"},
                {"xocs:funding-agency-matched-string": "Janssen Pharmaceutica NV"},
                {"xocs:funding-agency-matched-string": "Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson"},
                {"xocs:funding-agency-matched-string": "KAVI"},
                {"xocs:funding-agency-matched-string": "Karla Mellet, University of the Witwatersrand"},
                {"xocs:funding-agency-matched-string": "Kenyatta Hospital"},
                {"xocs:funding-agency-matched-string": "Netherlands Australia Thailand Research Collaboration, Bangkok"},
                {"xocs:funding-agency-matched-string": "Siriraj Hospital Department of Infectious Disease Faculty of Medicine, Bangkok"},
                {"xocs:funding-agency-matched-string": "Themba Lethu Research Centre"},
                {"xocs:funding-agency-matched-string": "UVRI Uganda Research Unit on AIDS, Entebbe"},
                {"xocs:funding-agency-matched-string": "Weerawat Manosuthi"},
                {"xocs:funding-agency-matched-string": "Yaoundé Central Hospital"},
                {
                    "xocs:funding-agency-matched-string": "Aga Khan University",
                    "xocs:funding-agency": "Bacha Khan University",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100017901",
                    "xocs:funding-agency-country": "http://sws.geonames.org/1168579/"
                },
                {
                    "xocs:funding-agency-matched-string": "MRC",
                    "xocs:funding-agency-acronym": "MRC",
                    "xocs:funding-agency": "Medical Research Council",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100000265",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2635167/"
                },
                {
                    "xocs:funding-agency-matched-string": "Makerere University",
                    "xocs:funding-agency-acronym": "MAK",
                    "xocs:funding-agency": "Makerere University",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100009914",
                    "xocs:funding-agency-country": "http://sws.geonames.org/226074/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2022-06-09T11:40:59.810Z",
            "xocs:funding-text": [
                {"$": "The authors would like to thank all the patients, all investigators and their teams at the following centres for their participation in SALIF: Cameroon: Pascale Abena Messomo Mbida, Cabinet Medical IDOC, Douala; Roselyne Toby, Yaoundé Central Hospital, Yaoundé. Kenya: Edwin Were, Partners in Prevention, Eldoret; Gaudensia Mutua, KAVI, Kangemi, Nairobi; Gina Ouattara, KAVI, Kenyatta Hospital, Nairobi; Lucas Otieno, Kombewa Clinical Trials Unit, Nyanza; Reena Shah, Aga Khan University, Nairobi. Senegal: Baye Moussa Samba, District Centre de Gaspard Kamara, Dakar; Kouro Bousso, Centre de Sante Domninique de Pikine, Pikine. South Africa: Lerato Mohapi, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto; Johan Lombaard, Josha Research, Bloemfontein; Rosie Mngqibisa, Enhancing Care Foundation Wentworth Hospital, Wentworth, Durban; Karla Mellet, University of the Witwatersrand, Helen Joseph Hospital, Themba Lethu Research Centre, Johannesburg; Gita Ramjee, HIV Prevention Research Unit, Medical Research Council, Westville, KwaZulu-Natal. Uganda: Paula Munderi, MRC/UVRI Uganda Research Unit on AIDS, Entebbe; Andrew Kambugu, Infectious Diseases Institute, Mulago Hospital Complex, Kampala; Cissy Kityo, Joint Clinical Research Centre, Kampala; Fred Collins Semitala, Makerere University Joint AIDS Program, Kampala; Francis Kiweewa, Makerere University Walter Reed Project, Kampala. Thailand: Anchalee Avihingsanon, HIV-NAT \u2013 The Netherlands Australia Thailand Research Collaboration, Bangkok; Weerawat Manosuthi, Bamrasnaradura Infectious Disease Institute, Amphur Mueang Nonthaburi; Khuanchai Supparatpinyo, Ries Chiang Mai University Hospital, Chiang Mai; Winai Ratanasuwan, Siriraj Hospital Department of Infectious Disease Faculty of Medicine, Bangkok. The authors acknowledge Scientific Pathways, part of Nucleus Global, for editorial assistance, funded by Janssen Pharmaceutica NV. Marjolein Jansen: employee of Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson. Perry Mohammed: employee of Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson. Ceyhun Bicer: received consulting fees from Janssen Pharmaceutica NV; Yvon van Delft: employee of Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson."},
                {"$": "The authors would like to thank all the patients, all investigators and their teams at the following centres for their participation in SALIF: Cameroon: Pascale Abena Messomo Mbida, Cabinet Medical IDOC, Douala; Roselyne Toby, Yaoundé Central Hospital, Yaoundé. Kenya: Edwin Were, Partners in Prevention, Eldoret; Gaudensia Mutua, KAVI, Kangemi, Nairobi; Gina Ouattara, KAVI, Kenyatta Hospital, Nairobi; Lucas Otieno, Kombewa Clinical Trials Unit, Nyanza; Reena Shah, Aga Khan University, Nairobi. Senegal: Baye Moussa Samba, District Centre de Gaspard Kamara, Dakar; Kouro Bousso, Centre de Sante Domninique de Pikine, Pikine. South Africa: Lerato Mohapi, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto; Johan Lombaard, Josha Research, Bloemfontein; Rosie Mngqibisa, Enhancing Care Foundation Wentworth Hospital, Wentworth, Durban; Karla Mellet, University of the Witwatersrand, Helen Joseph Hospital, Themba Lethu Research Centre, Johannesburg; Gita Ramjee, HIV Prevention Research Unit, Medical Research Council, Westville, KwaZulu-Natal. Uganda: Paula Munderi, MRC/UVRI Uganda Research Unit on AIDS, Entebbe; Andrew Kambugu, Infectious Diseases Institute, Mulago Hospital Complex, Kampala; Cissy Kityo, Joint Clinical Research Centre, Kampala; Fred Collins Semitala, Makerere University Joint AIDS Program, Kampala; Francis Kiweewa, Makerere University Walter Reed Project, Kampala. Thailand: Anchalee Avihingsanon, HIV-NAT \u2013 The Netherlands Australia Thailand Research Collaboration, Bangkok; Weerawat Manosuthi, Bamrasnaradura Infectious Disease Institute, Amphur Mueang Nonthaburi; Khuanchai Supparatpinyo, Ries Chiang Mai University Hospital, Chiang Mai; Winai Ratanasuwan, Siriraj Hospital Department of Infectious Disease Faculty of Medicine, Bangkok. The authors acknowledge Scientific Pathways, part of Nucleus Global, for editorial assistance, funded by Janssen Pharmaceutica NV."}
            ],
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Uganda",
                            "@afid": "60015879",
                            "@country": "uga",
                            "city": "Entebbe",
                            "organization": {"$": "MRC/UVRI Uganda Research Unit on AIDS"},
                            "affiliation-id": {"@afid": "60015879"},
                            "ce:source-text": "MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda"
                        },
                        "author": [{
                            "ce:given-name": "Paula",
                            "preferred-name": {
                                "ce:given-name": "Paula",
                                "ce:initials": "P.",
                                "ce:surname": "Munderi",
                                "ce:indexed-name": "Munderi P."
                            },
                            "@seq": "1",
                            "ce:initials": "P.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Munderi",
                            "@auid": "57191037895",
                            "ce:indexed-name": "Munderi P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Kenya",
                            "@afid": "123178472",
                            "@country": "ken",
                            "city": "Eldoret",
                            "organization": {"$": "Partners in Prevention"},
                            "affiliation-id": {"@afid": "123178472"},
                            "ce:source-text": "Partners in Prevention, Eldoret, Kenya"
                        },
                        "author": [{
                            "ce:given-name": "Edwin",
                            "preferred-name": {
                                "ce:given-name": "Edwin",
                                "ce:initials": "E.",
                                "ce:surname": "Were",
                                "ce:indexed-name": "Were E."
                            },
                            "@seq": "2",
                            "ce:initials": "E.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Were",
                            "@auid": "6603179809",
                            "ce:indexed-name": "Were E."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60016965",
                            "@country": "tha",
                            "organization": {"$": "HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)"},
                            "affiliation-id": {"@afid": "60016965"},
                            "ce:source-text": "HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Anchalee",
                            "preferred-name": {
                                "ce:given-name": "Anchalee",
                                "ce:initials": "A.",
                                "ce:surname": "Avihingsanon",
                                "ce:indexed-name": "Avihingsanon A."
                            },
                            "@seq": "3",
                            "ce:initials": "A.",
                            "@date-locked": "2023-01-18T05:16:58.450",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Avihingsanon",
                            "@auid": "57196347321",
                            "ce:indexed-name": "Avihingsanon A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60028190",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": {"@afid": "60028190"},
                            "ce:source-text": "Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Anchalee",
                            "preferred-name": {
                                "ce:given-name": "Anchalee",
                                "ce:initials": "A.",
                                "ce:surname": "Avihingsanon",
                                "ce:indexed-name": "Avihingsanon A."
                            },
                            "@seq": "3",
                            "ce:initials": "A.",
                            "@date-locked": "2023-01-18T05:16:58.450",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Avihingsanon",
                            "@auid": "57196347321",
                            "ce:indexed-name": "Avihingsanon A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Cameroon",
                            "@afid": "123178620",
                            "@country": "cmr",
                            "city": "Douala",
                            "organization": {"$": "Cabinet Medical IDOC"},
                            "affiliation-id": {"@afid": "123178620"},
                            "ce:source-text": "Cabinet Medical IDOC, Douala, Cameroon"
                        },
                        "author": [{
                            "ce:given-name": "Pascale A.M.",
                            "preferred-name": {
                                "ce:given-name": "Pascale A.M.",
                                "ce:initials": "P.A.M.",
                                "ce:surname": "Mbida",
                                "ce:indexed-name": "Mbida P.A.M."
                            },
                            "@seq": "4",
                            "ce:initials": "P.A.M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Mbida",
                            "@auid": "57211033214",
                            "ce:indexed-name": "Mbida P.A.M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "South Africa",
                            "@afid": "60016218",
                            "@country": "zaf",
                            "city": "Johannesburg",
                            "organization": [
                                {"$": "Perinatal HIV Research Unit"},
                                {"$": "University of the Witwatersrand"}
                            ],
                            "affiliation-id": {
                                "@afid": "60016218",
                                "@dptid": "103836547"
                            },
                            "ce:source-text": "Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa",
                            "@dptid": "103836547"
                        },
                        "author": [{
                            "ce:given-name": "Lerato",
                            "preferred-name": {
                                "ce:given-name": "Lerato",
                                "ce:initials": "L.",
                                "ce:surname": "Mohapi",
                                "ce:indexed-name": "Mohapi L."
                            },
                            "@seq": "5",
                            "ce:initials": "L.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Mohapi",
                            "@auid": "24734526800",
                            "ce:indexed-name": "Mohapi L."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Senegal",
                            "@afid": "123178306",
                            "@country": "sen",
                            "city": "Dakar",
                            "organization": {"$": "District Centre de Gaspard Kamara"},
                            "affiliation-id": {"@afid": "123178306"},
                            "ce:source-text": "District Centre de Gaspard Kamara, Dakar, Senegal"
                        },
                        "author": [{
                            "ce:given-name": "Samba B.",
                            "preferred-name": {
                                "ce:given-name": "Samba B.",
                                "ce:initials": "S.B.",
                                "ce:surname": "Moussa",
                                "ce:indexed-name": "Moussa S.B."
                            },
                            "@seq": "6",
                            "ce:initials": "S.B.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Moussa",
                            "@auid": "57211032927",
                            "ce:indexed-name": "Moussa S.B."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Netherlands",
                            "@afid": "118601347",
                            "@country": "nld",
                            "city": "Breda",
                            "organization": {"$": "Janssen-Cilag BV"},
                            "affiliation-id": {"@afid": "118601347"},
                            "ce:source-text": "Janssen-Cilag BV, Breda, Netherlands"
                        },
                        "author": [
                            {
                                "ce:given-name": "Marjolein",
                                "preferred-name": {
                                    "ce:given-name": "Marjolein",
                                    "ce:initials": "M.",
                                    "ce:surname": "Jansen",
                                    "ce:indexed-name": "Jansen M."
                                },
                                "@seq": "7",
                                "ce:initials": "M.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Jansen",
                                "@auid": "57211029130",
                                "ce:indexed-name": "Jansen M."
                            },
                            {
                                "ce:given-name": "Yvon",
                                "preferred-name": {
                                    "ce:given-name": "Yvon",
                                    "ce:initials": "Y.",
                                    "ce:surname": "van Delft",
                                    "ce:indexed-name": "van Delft Y."
                                },
                                "@seq": "10",
                                "ce:initials": "Y.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "van Delft",
                                "@auid": "35410941100",
                                "ce:indexed-name": "van Delft Y."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Belgium",
                            "@afid": "120331258",
                            "@country": "bel",
                            "city": "Antwerp",
                            "organization": {"$": "BICER Consulting and Research"},
                            "affiliation-id": {"@afid": "120331258"},
                            "ce:source-text": "BICER Consulting & Research, Antwerp, Belgium"
                        },
                        "author": [{
                            "ce:given-name": "Ceyhun",
                            "preferred-name": {
                                "ce:given-name": "Ceyhun",
                                "ce:initials": "C.",
                                "ce:surname": "Bicer",
                                "ce:indexed-name": "Bicer C."
                            },
                            "@seq": "8",
                            "ce:initials": "C.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Bicer",
                            "@auid": "57192910993",
                            "ce:indexed-name": "Bicer C."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United Kingdom",
                            "@afid": "113734673",
                            "@country": "gbr",
                            "city": "High Wycombe",
                            "organization": {"$": "Janssen Ltd"},
                            "affiliation-id": {"@afid": "113734673"},
                            "ce:source-text": "Janssen Ltd, High Wycombe, United Kingdom"
                        },
                        "author": [{
                            "ce:given-name": "Perry",
                            "preferred-name": {
                                "ce:given-name": "Perry",
                                "ce:initials": "P.",
                                "ce:surname": "Mohammed",
                                "ce:indexed-name": "Mohammed P."
                            },
                            "@seq": "9",
                            "ce:initials": "P.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Mohammed",
                            "@auid": "53871783200",
                            "ce:indexed-name": "Mohammed P."
                        }]
                    }
                ],
                "citation-title": "Switching at low HIV-1 RNA into fixed dose combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/ EFV in first-line suppressed patients living with HIV",
                "abstracts": "© 2019. The Authors.Background: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Objectives: Switching at Low HIV-1 RNA into Fixed Dose Combinations (SALIF) compared RPV with efavirenz (EFV), both as STRs with TDF and FTC, in maintaining virologic suppression. Methods: SALIF was a phase 3b, randomised, open-label, non-inferiority study in virologically suppressed adults (HIV-1 RNA < 50 copies/mL) on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) in Cameroon, Kenya, Senegal, South Africa, Uganda and Thailand. Patients (N = 426), stratified by NNRTI use, were randomised 1:1 to receive TDF/FTC/RPV (300/200/25 mg qd) or TDF/FTC/EFV (300/200/600 mg qd). Primary endpoint was proportion of patients with virologic suppression (HIV-1 RNA < 400 copies/mL) at week 48 (intent-to-treat, modified Food and Drug Administration Snapshot, 10% non-inferiority margin). Results: Patients received TDF/FTC/RPV (n = 213) or TDF/FTC/EFV (n = 211). At week 48, virologic suppression was maintained in 200/213 (93.9%) patients in the RPV arm and 203/211 (96.2%) in the EFV arm (difference \u20132.3%; 95% confidence interval: -6.4, +1.8), demonstrating non-inferiority of TDF/FTC/RPV. One patient in each arm experienced virologic failure without treatment-emergent resistance. Twenty-seven patients discontinued prematurely (8.0% RPV vs. 4.7% EFV), the most frequent reasons being adverse events (3.3% vs. 0.5%, respectively), site closure (1.9% vs. 0.5%), loss to follow-up (0.9% vs. 1.4%) and consent withdrawal (0.9% vs. 1.4%). Conclusion: In adults with suppressed viral load on first-line NNRTI-based ART in LMICs, switching to an STR of TDF/FTC/RPV was non-inferior to TDF/FTC/EFV in maintaining high rates of viral suppression with a comparable tolerability profile.",
                "correspondence": {
                    "affiliation": {
                        "country": "United Kingdom",
                        "@country": "gbr",
                        "city": "High Wycombe",
                        "organization": {"$": "Janssen Ltd"},
                        "ce:source-text": "Janssen Ltd, High Wycombe, United Kingdom"
                    },
                    "person": {
                        "ce:given-name": "Perry",
                        "ce:initials": "P.",
                        "ce:surname": "Mohammed",
                        "ce:indexed-name": "Mohammed P."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "LMIC",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "SALIF",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "Single-Tablet-Regimen",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "Treatment-emergent Resistance",
                            "@xml:lang": "eng"
                        },
                        {
                            "$": "Virologically suppressed adults",
                            "@xml:lang": "eng"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://sajhivmed.org.za/index.php/hivmed/article/view/949/1527",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Southern African Journal of HIV Medicine",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {"voliss": {
                        "@volume": "20",
                        "@issue": "1"
                    }},
                    "@type": "j",
                    "sourcetitle": "Southern African Journal of HIV Medicine",
                    "publicationdate": {
                        "month": "07",
                        "year": "2019",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "23 July 2019"
                        },
                        "day": "23"
                    },
                    "codencode": "SAJHB",
                    "sourcetitle-abbrev": "South. Afr. J. HIV Med.",
                    "@country": "zaf",
                    "issn": [
                        {
                            "$": "20786751",
                            "@type": "electronic"
                        },
                        {
                            "$": "16089693",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2019"},
                    "publisher": {
                        "publishername": "AOSIS (pty) Ltd",
                        "ce:e-address": {
                            "$": "publishing@aosis.co.za",
                            "@type": "email"
                        }
                    },
                    "article-number": "a949",
                    "@srcid": "93433"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "17",
                                    "classification-description": "Public Health, Social Medicine and Epidemiology"
                                },
                                {
                                    "classification-code": "29",
                                    "classification-description": "Clinical and Experimental Biochemistry"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "38",
                                    "classification-description": "Adverse Reactions Titles"
                                },
                                {
                                    "classification-code": "4",
                                    "classification-description": "Microbiology: Bacteriology, Mycology, Parasitology and Virology"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2725"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": {
                        "@source": "esbd",
                        "chemical": [
                            {
                                "cas-registry-number": [
                                    {"$": "9000-86-6"},
                                    {"$": "9014-30-6"}
                                ],
                                "enzyme-commission-number": "EC 2.6.1.2",
                                "chemical-name": "alanine aminotransferase"
                            },
                            {
                                "cas-registry-number": [
                                    {"$": "9000-90-2"},
                                    {"$": "9000-92-4"},
                                    {"$": "9001-19-8"}
                                ],
                                "enzyme-commission-number": "EC 3.2.1.1",
                                "chemical-name": "amylase"
                            },
                            {
                                "cas-registry-number": "9000-97-9",
                                "enzyme-commission-number": "EC 2.6.1.1",
                                "chemical-name": "aspartate aminotransferase"
                            },
                            {
                                "cas-registry-number": "154598-52-4",
                                "chemical-name": "efavirenz"
                            },
                            {
                                "cas-registry-number": [
                                    {"$": "137530-41-7"},
                                    {"$": "143491-54-7"},
                                    {"$": "143491-57-0"}
                                ],
                                "chemical-name": "emtricitabine"
                            },
                            {
                                "cas-registry-number": [
                                    {"$": "50-99-7"},
                                    {"$": "84778-64-3"}
                                ],
                                "chemical-name": "glucose"
                            },
                            {
                                "cas-registry-number": [
                                    {"$": "500287-72-9"},
                                    {"$": "700361-47-3"}
                                ],
                                "chemical-name": "rilpivirine"
                            },
                            {
                                "cas-registry-number": "202138-50-9",
                                "chemical-name": "tenofovir disoproxil"
                            }
                        ]
                    }}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "The authors would like to thank all the patients, all investigators and their teams at the following centres for their participation in SALIF: Cameroon: Pascale Abena Messomo Mbida, Cabinet Medical IDOC, Douala; Roselyne Toby, Yaoundé Central Hospital, Yaoundé. Kenya: Edwin Were, Partners in Prevention, Eldoret; Gaudensia Mutua, KAVI, Kangemi, Nairobi; Gina Ouattara, KAVI, Kenyatta Hospital, Nairobi; Lucas Otieno, Kombewa Clinical Trials Unit, Nyanza; Reena Shah, Aga Khan University, Nairobi. Senegal: Baye Moussa Samba, District Centre de Gaspard Kamara, Dakar; Kouro Bousso, Centre de Sante Domninique de Pikine, Pikine. South Africa: Lerato Mohapi, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto; Johan Lombaard, Josha Research, Bloemfontein; Rosie Mngqibisa, Enhancing Care Foundation Wentworth Hospital, Wentworth, Durban; Karla Mellet, University of the Witwatersrand, Helen Joseph Hospital, Themba Lethu Research Centre, Johannesburg; Gita Ramjee, HIV Prevention Research Unit, Medical Research Council, Westville, KwaZulu-Natal. Uganda: Paula Munderi, MRC/UVRI Uganda Research Unit on AIDS, Entebbe; Andrew Kambugu, Infectious Diseases Institute, Mulago Hospital Complex, Kampala; Cissy Kityo, Joint Clinical Research Centre, Kampala; Fred Collins Semitala, Makerere University Joint AIDS Program, Kampala; Francis Kiweewa, Makerere University Walter Reed Project, Kampala. Thailand: Anchalee Avihingsanon, HIV-NAT \u2013 The Netherlands Australia Thailand Research Collaboration, Bangkok; Weerawat Manosuthi, Bamrasnaradura Infectious Disease Institute, Amphur Mueang Nonthaburi; Khuanchai Supparatpinyo, Ries Chiang Mai University Hospital, Chiang Mai; Winai Ratanasuwan, Siriraj Hospital Department of Infectious Disease Faculty of Medicine, Bangkok. The authors acknowledge Scientific Pathways, part of Nucleus Global, for editorial assistance, funded by Janssen Pharmaceutica NV. Marjolein Jansen: employee of Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson. Perry Mohammed: employee of Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson. Ceyhun Bicer: received consulting fees from Janssen Pharmaceutica NV; Yvon van Delft: employee of Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson.",
                        "@xml:lang": "eng"
                    },
                    "grant": {
                        "grant-acronym": "WITS",
                        "grant-agency": {
                            "@iso-code": "zaf",
                            "$": "University of the Witwatersrand, Johannesburg"
                        },
                        "grant-agency-id": "100009467"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2019 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "26",
                    "@timestamp": "BST 03:08:33",
                    "@year": "2019",
                    "@month": "09"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2002915589",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "920419051",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20190678065",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "20191837167",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20192787697",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "2019001171183X",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85072338061",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85072338061",
                            "@idtype": "SGR"
                        }
                    ],
                    "ce:doi": "10.4102/sajhivmed.v20i1.949"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "48",
                "reference": [
                    {
                        "ref-fulltext": "British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). August 2016. [cited 2019 Apr 2]. Available from: https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines2016-interim-update.pdf.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines2016-interim-update.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85072308674",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "August cited 2019 Apr 2.",
                            "ref-sourcetitle": "British HIV Association Guidelines for the Treatment of HIV-1-Positive Adults with Antiretroviral Therapy 2015 (2016 Interim Update"
                        },
                        "ce:source-text": "British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). August 2016. [cited 2019 Apr 2]. Available from: https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines2016-interim-update.pdf."
                    },
                    {
                        "ref-fulltext": "AIDSinfo. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018 [cited 2019 Apr 2] Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {
                                "websitename": "AIDSinfo",
                                "ce:e-address": {
                                    "$": "https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf",
                                    "@type": "email"
                                }
                            },
                            "ref-title": {"ref-titletext": "Panel on antiretroviral guidelines for adults and adolescents"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84857239027",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "cited 2019 Apr 2",
                            "ref-sourcetitle": "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents"
                        },
                        "ce:source-text": "AIDSinfo. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018 [cited 2019 Apr 2] Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."
                    },
                    {
                        "ref-fulltext": "European AIDS Clinical Society/EACS. EACS guidelines 9.0. October 2017 [cited 2019 Apr 2] Available from: http://www.eacsociety.org/files/guidelines_9.0-english.pdf.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {
                                "websitename": "European AIDS Clinical Society/EACS",
                                "ce:e-address": {
                                    "$": "http://www.eacsociety.org/files/guidelines_9.0-english.pdf",
                                    "@type": "email"
                                }
                            },
                            "refd-itemidlist": {"itemid": {
                                "$": "85050572673",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "October cited 2019 Apr 2",
                            "ref-sourcetitle": "EACS Guidelines 9.0"
                        },
                        "ce:source-text": "European AIDS Clinical Society/EACS. EACS guidelines 9.0. October 2017 [cited 2019 Apr 2] Available from: http://www.eacsociety.org/files/guidelines_9.0-english.pdf."
                    },
                    {
                        "ref-fulltext": "World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. July 2018. [cited 2019 Apr 2] Available from: http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18eng.pdf?ua=1.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {
                                "websitename": "World Health Organization",
                                "ce:e-address": {
                                    "$": "http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18eng.pdf?ua=1",
                                    "@type": "email"
                                }
                            },
                            "refd-itemidlist": {"itemid": {
                                "$": "85056136176",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "July cited 2019 Apr 2",
                            "ref-sourcetitle": "Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV"
                        },
                        "ce:source-text": "World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. July 2018. [cited 2019 Apr 2] Available from: http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18eng.pdf?ua=1."
                    },
                    {
                        "ref-fulltext": "Hoffmann C, Wolf E, Schewe K, et al. CNS Toxicity of dolutegravir is not associated with psychiatric conditions or higher plasma exposure. Abstract 424, presented at: Conference on Retroviruses and Opportunistic Infections; 2018 Mar 4\u20137; Boston, MA. Boston, MA: CROI Foundation/IAS\u2013USA; 2018.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "CNS Toxicity of dolutegravir is not associated with psychiatric conditions or higher plasma exposure"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "424",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85066492457",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Abstract 2018 Mar 4\u20137; Boston, MA. Boston, MA: CROI Foundation/IAS\u2013USA",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Hoffmann",
                                        "ce:indexed-name": "Hoffmann C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Wolf",
                                        "ce:indexed-name": "Wolf E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Schewe",
                                        "ce:indexed-name": "Schewe K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Conference on Retroviruses and Opportunistic Infections"
                        },
                        "ce:source-text": "Hoffmann C, Wolf E, Schewe K, et al. CNS Toxicity of dolutegravir is not associated with psychiatric conditions or higher plasma exposure. Abstract 424, presented at: Conference on Retroviruses and Opportunistic Infections; 2018 Mar 4\u20137; Boston, MA. Boston, MA: CROI Foundation/IAS\u2013USA; 2018."
                    },
                    {
                        "ref-fulltext": "Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229\u2013237. https://doi.org/10.1016/S0140-6736(11)60983-5",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S0140-6736(11)60983-5",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "79960358849",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "9787"
                                },
                                "pagerange": {
                                    "@first": "229",
                                    "@last": "237"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Andrade-Villanueva",
                                        "ce:indexed-name": "Andrade-Villanueva J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Clotet",
                                        "ce:indexed-name": "Clotet B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229\u2013237. https://doi.org/10.1016/S0140-6736(11)60983-5"
                    },
                    {
                        "ref-fulltext": "Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238\u2013246. https://doi.org/10.1016/S0140-6736(11)60936-7",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S0140-6736(11)60936-7",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "79960381844",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "9787"
                                },
                                "pagerange": {
                                    "@first": "238",
                                    "@last": "246"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Cahn",
                                        "ce:indexed-name": "Cahn P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Grinsztejn",
                                        "ce:indexed-name": "Grinsztejn B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238\u2013246. https://doi.org/10.1016/S0140-6736(11)60936-7"
                    },
                    {
                        "ref-fulltext": "Boehringer Ingelheim. Nevirapine PI: Nevirapine prescribing information. 2016 [cited 2019 Mar]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Viramune/Viramune.pdf",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {
                                "websitename": "Boehringer Ingelheim",
                                "ce:e-address": {
                                    "$": "https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Viramune/Viramune.pdf",
                                    "@type": "email"
                                }
                            },
                            "refd-itemidlist": {"itemid": {
                                "$": "85072314707",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "cited 2019 Mar.",
                            "ref-sourcetitle": "Nevirapine PI: Nevirapine Prescribing Information"
                        },
                        "ce:source-text": "Boehringer Ingelheim. Nevirapine PI: Nevirapine prescribing information. 2016 [cited 2019 Mar]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Viramune/Viramune.pdf"
                    },
                    {
                        "ref-fulltext": "WHO. WHO Statement on DTG \u2013 Geneva 18 May 2018. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception. 2018 [cited 2019 Apr 2]. Available from: https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {
                                "websitename": "WHO",
                                "ce:e-address": {
                                    "$": "https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf",
                                    "@type": "email"
                                }
                            },
                            "refd-itemidlist": {"itemid": {
                                "$": "85048544311",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "cited 2019 Apr 2.",
                            "ref-sourcetitle": "WHO Statement on DTG \u2013 Geneva 18 May 2018. Potential Safety Issue Affecting Women Living with HIV Using Dolutegravir at the Time of Conception"
                        },
                        "ce:source-text": "WHO. WHO Statement on DTG \u2013 Geneva 18 May 2018. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception. 2018 [cited 2019 Apr 2]. Available from: https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf."
                    },
                    {
                        "ref-fulltext": "Vitoria M, Ford N, Doherty M, Flexner C. Simplification of antiretroviral therapy: A necessary step in the public health response to HIV/AIDS in resource-limited settings. Antivir Ther. 2014;19 Suppl 3:31\u201337. https://doi.org/10.3851/IMP2898",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.3851/IMP2898",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Simplification of antiretroviral therapy: A necessary step in the public health response to HIV/AIDS in resource-limited settings"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84964290970",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "19"},
                                "pagerange": {
                                    "@first": "31",
                                    "@last": "37"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Vitoria",
                                    "ce:indexed-name": "Vitoria M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Ford",
                                    "ce:indexed-name": "Ford N."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Doherty",
                                    "ce:indexed-name": "Doherty M."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Flexner",
                                    "ce:indexed-name": "Flexner C."
                                }
                            ]},
                            "ref-sourcetitle": "Antivir Ther"
                        },
                        "ce:source-text": "Vitoria M, Ford N, Doherty M, Flexner C. Simplification of antiretroviral therapy: A necessary step in the public health response to HIV/AIDS in resource-limited settings. Antivir Ther. 2014;19 Suppl 3:31\u201337. https://doi.org/10.3851/IMP2898"
                    },
                    {
                        "ref-fulltext": "Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl). 2011;3:35\u201344. https://doi.org/10.2147/HIV.S14559",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.2147/HIV.S14559",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85014459203",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "3"},
                                "pagerange": {
                                    "@first": "35",
                                    "@last": "44"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Ford",
                                    "ce:indexed-name": "Ford N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Lee",
                                    "ce:indexed-name": "Lee J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "I.",
                                    "@_fa": "true",
                                    "ce:surname": "Andrieux-Meyer",
                                    "ce:indexed-name": "Andrieux-Meyer I."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Calmy",
                                    "ce:indexed-name": "Calmy A."
                                }
                            ]},
                            "ref-sourcetitle": "HIV AIDS (Auckl)"
                        },
                        "ce:source-text": "Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl). 2011;3:35\u201344. https://doi.org/10.2147/HIV.S14559"
                    },
                    {
                        "ref-fulltext": "Janssen Pharmaceutica, N.V. Janssen Global Public Health: HIV medicines access & partnerships program. 2014. [cited 2019 Apr 2]. Available from: http://partnerships.ifpma.org/uploads/documents/138_1408024768.pdf.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://partnerships.ifpma.org/uploads/documents/138_1408024768.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85041841241",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Pharmaceutica, cited 2019 Apr 2.",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "@_fa": "true",
                                    "ce:surname": "Janssen",
                                    "ce:indexed-name": "Janssen"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.V.",
                                    "@_fa": "true",
                                    "ce:surname": "Janssen",
                                    "ce:indexed-name": "Janssen N.V."
                                }
                            ]},
                            "ref-sourcetitle": "Global Public Health: HIV Medicines Access & Partnerships Program"
                        },
                        "ce:source-text": "Janssen Pharmaceutica, N.V. Janssen Global Public Health: HIV medicines access & partnerships program. 2014. [cited 2019 Apr 2]. Available from: http://partnerships.ifpma.org/uploads/documents/138_1408024768.pdf."
                    },
                    {
                        "ref-fulltext": "Domingo P, Ribera E. Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR. Enferm Infecc Microbiol Clín. 2013;31 Suppl 2:20\u201329. https://doi.org/10.1016/S0213-005X(13)70139-3",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S0213-005X(13)70139-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Data on rilpivirine in treatment-naïve patients. Lessons from Echo, thrive and Star"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84888350417",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {
                                    "@first": "20",
                                    "@last": "29"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Domingo",
                                    "ce:indexed-name": "Domingo P."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Ribera",
                                    "ce:indexed-name": "Ribera E."
                                }
                            ]},
                            "ref-sourcetitle": "Enferm Infecc Microbiol Clín"
                        },
                        "ce:source-text": "Domingo P, Ribera E. Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR. Enferm Infecc Microbiol Clín. 2013;31 Suppl 2:20\u201329. https://doi.org/10.1016/S0213-005X(13)70139-3"
                    },
                    {
                        "ref-fulltext": "Yagudina R, Kulikov A, Babiy VV. Potential long-term cost savings in treatment of naïve HIV-infected patients with rilpivirine/tenofovir/emtricitabine (single tablet regimen) in the Russian Federation. Value Health. J Int Soc Pharmacoeconomics Outcomes Res 2015;18(7):A581. https://doi.org/10.1016/j.jval.2015.09.1941",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.jval.2015.09.1941",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Potential long-term cost savings in treatment of naïve HIV-infected patients with rilpivirine/tenofovir/emtricitabine (single tablet regimen) in the Russian Federation. Value health"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85073764242",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "18",
                                    "@issue": "7"
                                },
                                "pagerange": {"@first": "A581"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Yagudina",
                                    "ce:indexed-name": "Yagudina R."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Kulikov",
                                    "ce:indexed-name": "Kulikov A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "V.V.",
                                    "@_fa": "true",
                                    "ce:surname": "Babiy",
                                    "ce:indexed-name": "Babiy V.V."
                                }
                            ]},
                            "ref-sourcetitle": "J Int Soc Pharmacoeconomics Outcomes Res"
                        },
                        "ce:source-text": "Yagudina R, Kulikov A, Babiy VV. Potential long-term cost savings in treatment of naïve HIV-infected patients with rilpivirine/tenofovir/emtricitabine (single tablet regimen) in the Russian Federation. Value Health. J Int Soc Pharmacoeconomics Outcomes Res 2015;18(7):A581. https://doi.org/10.1016/j.jval.2015.09.1941"
                    },
                    {
                        "ref-fulltext": "Neogi U, Häggblom A, Singh K, et al. Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. J Antimicrob Chemother. 2016;71(2):367\u2013371. https://doi.org/10.1093/jac/dkv359",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1093/jac/dkv359",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- And middle-income countries"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84959899694",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "71",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "367",
                                    "@last": "371"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Neogi",
                                        "ce:indexed-name": "Neogi U."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Häggblom",
                                        "ce:indexed-name": "Haggblom A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Singh",
                                        "ce:indexed-name": "Singh K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Antimicrob Chemother"
                        },
                        "ce:source-text": "Neogi U, Häggblom A, Singh K, et al. Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. J Antimicrob Chemother. 2016;71(2):367\u2013371. https://doi.org/10.1093/jac/dkv359"
                    },
                    {
                        "ref-fulltext": "Gianotti N, Poli A, Nozza S, et al. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. J Int AIDS Soc. 2015;18:20037. https://doi.org/10.7448/IAS.18.1.20037",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.7448/IAS.18.1.20037",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84938236681",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "18"},
                                "pagerange": {"@first": "20037"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Gianotti",
                                        "ce:indexed-name": "Gianotti N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Poli",
                                        "ce:indexed-name": "Poli A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Nozza",
                                        "ce:indexed-name": "Nozza S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Int AIDS Soc"
                        },
                        "ce:source-text": "Gianotti N, Poli A, Nozza S, et al. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. J Int AIDS Soc. 2015;18:20037. https://doi.org/10.7448/IAS.18.1.20037"
                    },
                    {
                        "ref-fulltext": "Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5(1):38\u201347. https://doi.org/10.1097/COH.0b013e3283339b41",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/COH.0b013e3283339b41",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Improving first-line antiretroviral therapy in resource-limited settings"},
                            "refd-itemidlist": {"itemid": {
                                "$": "74349127079",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "38",
                                    "@last": "47"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Ford",
                                    "ce:indexed-name": "Ford N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Calmy",
                                    "ce:indexed-name": "Calmy A."
                                }
                            ]},
                            "ref-sourcetitle": "Curr Opin HIV AIDS"
                        },
                        "ce:source-text": "Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5(1):38\u201347. https://doi.org/10.1097/COH.0b013e3283339b41"
                    },
                    {
                        "ref-fulltext": "EDURANT (rilpivirine) prescribing information. Revised 02/2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202022s011lbl.pdf",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202022s011lbl.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062374297",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Revised 02",
                            "ref-sourcetitle": "EDURANT (Rilpivirine) Prescribing Information"
                        },
                        "ce:source-text": "EDURANT (rilpivirine) prescribing information. Revised 02/2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202022s011lbl.pdf"
                    },
                    {
                        "ref-fulltext": "Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18(1):776. https://doi.org/10.4102/sajhivmed.v18i1.776",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.4102/sajhivmed.v18i1.776",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Adult antiretroviral therapy guidelines 2017"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85029095315",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "18",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "776"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Meintjes",
                                        "ce:indexed-name": "Meintjes G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Moorhouse",
                                        "ce:indexed-name": "Moorhouse M.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Carmona",
                                        "ce:indexed-name": "Carmona S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "South Afr J HIV Med"
                        },
                        "ce:source-text": "Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18(1):776. https://doi.org/10.4102/sajhivmed.v18i1.776"
                    },
                    {
                        "ref-fulltext": "Manosuthi W, Ongwandee S, Bhakeecheep S, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015;12:12. https://doi.org/10.1186/s12981-015-0053-z",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1186/s12981-015-0053-z",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84928230979",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {"@first": "12"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Manosuthi",
                                        "ce:indexed-name": "Manosuthi W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ongwandee",
                                        "ce:indexed-name": "Ongwandee S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Bhakeecheep",
                                        "ce:indexed-name": "Bhakeecheep S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS Res Ther"
                        },
                        "ce:source-text": "Manosuthi W, Ongwandee S, Bhakeecheep S, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015;12:12. https://doi.org/10.1186/s12981-015-0053-z"
                    },
                    {
                        "ref-fulltext": "Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60(1):33\u201342. https://doi.org/10.1097/QAI.0b013e31824d006e",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAI.0b013e31824d006e",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84862777419",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "60",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "33",
                                    "@last": "42"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Cahn",
                                        "ce:indexed-name": "Cahn P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60(1):33\u201342. https://doi.org/10.1097/QAI.0b013e31824d006e"
                    },
                    {
                        "ref-fulltext": "Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/ tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28(3):335\u2013344. https://doi.org/10.1097/QAD.0000000000000087",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAD.0000000000000087",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Simplification to rilpivirine/emtricitabine/ tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84894107031",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "335",
                                    "@last": "344"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Palella",
                                        "ce:suffix": "Jr",
                                        "ce:indexed-name": "Palella F.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Fisher",
                                        "ce:indexed-name": "Fisher M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Tebas",
                                        "ce:indexed-name": "Tebas P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/ tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28(3):335\u2013344. https://doi.org/10.1097/QAD.0000000000000087"
                    },
                    {
                        "ref-fulltext": "Rokx C, Verbon A, Rijnders BJ. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF. AIDS Res Hum Retroviruses. 2015;31(4): 363\u2013367. https://doi.org/10.1089/aid.2014.0278",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1089/aid.2014.0278",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84964267990",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "363",
                                    "@last": "367"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Rokx",
                                    "ce:indexed-name": "Rokx C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Verbon",
                                    "ce:indexed-name": "Verbon A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Rijnders",
                                    "ce:indexed-name": "Rijnders B.J."
                                }
                            ]},
                            "ref-sourcetitle": "AIDS Res Hum Retroviruses"
                        },
                        "ce:source-text": "Rokx C, Verbon A, Rijnders BJ. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF. AIDS Res Hum Retroviruses. 2015;31(4): 363\u2013367. https://doi.org/10.1089/aid.2014.0278"
                    },
                    {
                        "ref-fulltext": "van Lunzen J, Antinori A, Cohen CJ, et al. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251\u2013259. https://doi.org/10.1097/QAD.0000000000000911",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAD.0000000000000911",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Rilpivirine vs. Efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84952947838",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "251",
                                    "@last": "259"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "van Lunzen",
                                        "ce:indexed-name": "van Lunzen J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Antinori",
                                        "ce:indexed-name": "Antinori A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen C.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "van Lunzen J, Antinori A, Cohen CJ, et al. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251\u2013259. https://doi.org/10.1097/QAD.0000000000000911"
                    },
                    {
                        "ref-fulltext": "Collins SE, Grant PM, Uwinkindi F, et al. A randomized switch from nevirapine-based antiretroviral therapy to single tablet rilpivirine/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed human immunodeficiency virus-1-infected Rwandans. Open Forum Infect Dis. 2016;3(3):ofw141. eCollection 2016 Sep.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "A randomized switch from nevirapine-based antiretroviral therapy to single tablet rilpivirine/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed human immunodeficiency virus-1-infected Rwandans"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85015964740",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "ofw141"}
                            },
                            "ref-text": "eCollection 2016 Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Collins",
                                        "ce:indexed-name": "Collins S.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Grant",
                                        "ce:indexed-name": "Grant P.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Uwinkindi",
                                        "ce:indexed-name": "Uwinkindi F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Open Forum Infect Dis"
                        },
                        "ce:source-text": "Collins SE, Grant PM, Uwinkindi F, et al. A randomized switch from nevirapine-based antiretroviral therapy to single tablet rilpivirine/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed human immunodeficiency virus-1-infected Rwandans. Open Forum Infect Dis. 2016;3(3):ofw141. eCollection 2016 Sep."
                    },
                    {
                        "ref-fulltext": "European Medicines Agency. Eviplera EPAR and SmPC. [updated 2017 Dec 19; cited 2018 Nov] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002312/WC500118802.pdf",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {
                                "websitename": "European Medicines Agency",
                                "ce:e-address": {
                                    "$": "http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002312/WC500118802.pdf",
                                    "@type": "email"
                                }
                            },
                            "refd-itemidlist": {"itemid": {
                                "$": "85072324534",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "updated Dec 19; cited 2018 Nov",
                            "ref-sourcetitle": "Eviplera EPAR and SmPC"
                        },
                        "ce:source-text": "European Medicines Agency. Eviplera EPAR and SmPC. [updated 2017 Dec 19; cited 2018 Nov] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002312/WC500118802.pdf"
                    },
                    {
                        "ref-fulltext": "Gilead Sciences. Complera prescribing information. 2017 [cited 2019 Apr 2]. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/complera/complera_pi.ashx.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {
                                "websitename": "Gilead Sciences",
                                "ce:e-address": {
                                    "$": "http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/complera/complera_pi.ashx",
                                    "@type": "email"
                                }
                            },
                            "refd-itemidlist": {"itemid": {
                                "$": "85072339909",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "cited 2019 Apr 2.",
                            "ref-sourcetitle": "Complera Prescribing Information"
                        },
                        "ce:source-text": "Gilead Sciences. Complera prescribing information. 2017 [cited 2019 Apr 2]. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/complera/complera_pi.ashx."
                    },
                    {
                        "ref-fulltext": "European Medicines Agency. Edurant EPAR and SmPC. 2018. [cited 2018 Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {
                                "websitename": "European Medicines Agency",
                                "ce:e-address": {
                                    "$": "http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf",
                                    "@type": "email"
                                }
                            },
                            "refd-itemidlist": {"itemid": {
                                "$": "85072332553",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "cited 2018 Nov.",
                            "ref-sourcetitle": "Edurant EPAR and SmPC"
                        },
                        "ce:source-text": "European Medicines Agency. Edurant EPAR and SmPC. 2018. [cited 2018 Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf."
                    },
                    {
                        "ref-fulltext": "Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2016;72(3):289\u2013296. https://doi.org/10.1097/QAI.0000000000000968",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAI.0000000000000968",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Pharmacokinetics of rilpivirine in HIV-infected pregnant women"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84959196606",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "72",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "289",
                                    "@last": "296"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Tran",
                                        "ce:indexed-name": "Tran A.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Best",
                                        "ce:indexed-name": "Best B.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Stek",
                                        "ce:indexed-name": "Stek A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2016;72(3):289\u2013296. https://doi.org/10.1097/QAI.0000000000000968"
                    },
                    {
                        "ref-fulltext": "Colbers A, Schalkwijk S, Konopnicki D, et al. Substantially lower rilpivirine plasma concentrations during pregnancy. Abstract 754 presented at: Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13\u201316; Seattle, WA. Seattle, WA: CROI Foundation/IAS\u2013USA; 2017.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Substantially lower rilpivirine plasma concentrations during pregnancy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "754",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85072314280",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Abstract 2017 Feb 13\u201316; Seattle, WA. Seattle, WA: CROI Foundation/IAS\u2013USA",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Colbers",
                                        "ce:indexed-name": "Colbers A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Schalkwijk",
                                        "ce:indexed-name": "Schalkwijk S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Konopnicki",
                                        "ce:indexed-name": "Konopnicki D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Conference on Retroviruses and Opportunistic Infections"
                        },
                        "ce:source-text": "Colbers A, Schalkwijk S, Konopnicki D, et al. Substantially lower rilpivirine plasma concentrations during pregnancy. Abstract 754 presented at: Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13\u201316; Seattle, WA. Seattle, WA: CROI Foundation/IAS\u2013USA; 2017."
                    },
                    {
                        "ref-fulltext": "Osiyemi O, Yasin S, Zorrilla C, et al. Pharmacokinetics of total and unbound Rilpivirine in HIV-1\u2013infected pregnant women. Abstract 35 presented at: 7th International Workshop on HIV & Women; 2017 Feb 11\u201312; Seattle, WA. Amsterdam: Virology Education; 2017. [cited 2019 Apr 2] Available from: http://regist2.virology-education.com/2017/7hivwomen/Abstractbook.pdf.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://regist2.virology-education.com/2017/7hivwomen/Abstractbook.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Pharmacokinetics of total and unbound Rilpivirine in HIV-1\u2013infected pregnant women"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85032806111",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Abstract 35: 2017 Feb 11\u201312; Seattle, WA. Amsterdam: Virology Education; cited 2019 Apr 2",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.",
                                        "@_fa": "true",
                                        "ce:surname": "Osiyemi",
                                        "ce:indexed-name": "Osiyemi O."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Yasin",
                                        "ce:indexed-name": "Yasin S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Zorrilla",
                                        "ce:indexed-name": "Zorrilla C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "7th International Workshop on HIV & Women"
                        },
                        "ce:source-text": "Osiyemi O, Yasin S, Zorrilla C, et al. Pharmacokinetics of total and unbound Rilpivirine in HIV-1\u2013infected pregnant women. Abstract 35 presented at: 7th International Workshop on HIV & Women; 2017 Feb 11\u201312; Seattle, WA. Amsterdam: Virology Education; 2017. [cited 2019 Apr 2] Available from: http://regist2.virology-education.com/2017/7hivwomen/Abstractbook.pdf."
                    },
                    {
                        "ref-fulltext": "The Antiretroviral Pregnancy Registry. Interim Report: 1 January 1989 through 31 January 2018 [issued 2018 Jun; cited 2019 Apr 2]. Available from: http://www.apregistry.com/forms/interim_report.pdf.",
                        "@id": "32",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://www.apregistry.com/forms/interim_report.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84875038932",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "The Antiretroviral Pregnancy Registry. 1 January 1989 through 31 January 2018 issued 2018 Jun; cited 2019 Apr 2.",
                            "ref-sourcetitle": "Interim Report"
                        },
                        "ce:source-text": "The Antiretroviral Pregnancy Registry. Interim Report: 1 January 1989 through 31 January 2018 [issued 2018 Jun; cited 2019 Apr 2]. Available from: http://www.apregistry.com/forms/interim_report.pdf."
                    },
                    {
                        "ref-fulltext": "Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. [cited 2019 Apr 2]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.",
                        "@id": "33",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission"},
                            "refd-itemidlist": {"itemid": {
                                "$": "80055061614",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "cited 2019 Apr 2.",
                            "ref-sourcetitle": "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States"
                        },
                        "ce:source-text": "Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. [cited 2019 Apr 2]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf."
                    },
                    {
                        "ref-fulltext": "Munderi P, Were E, Avihingsanon A, et al. SALIF trial: Switching suppressed first-line patients to tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is non-inferior to TDF/FTC/efavirenz (TDF/FTC/EFV) and could be an alternative treatment option in LMICs. Abstract THAB0104 presented at: AIDS; 2016 Jul 18\u201322; Durban, South Africa. New York: Wiley; 2016 [cited 2018 Apr 2] Available from https://onlinelibrary.wiley.com/doi/epdf/10.7448/IAS.19.6.21264.",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://onlinelibrary.wiley.com/doi/epdf/10.7448/IAS.19.6.21264",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "SALIF trial: Switching suppressed first-line patients to tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is non-inferior to TDF/FTC/efavirenz (TDF/FTC/EFV) and could be an alternative treatment option in LMICs"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85072337125",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "AIDS; 2016 Jul 18\u201322; Durban, South Africa. New York: Wiley; cited 2018 Apr 2",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Munderi",
                                        "ce:indexed-name": "Munderi P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Were",
                                        "ce:indexed-name": "Were E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Avihingsanon",
                                        "ce:indexed-name": "Avihingsanon A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Abstract THAB0104"
                        },
                        "ce:source-text": "Munderi P, Were E, Avihingsanon A, et al. SALIF trial: Switching suppressed first-line patients to tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is non-inferior to TDF/FTC/efavirenz (TDF/FTC/EFV) and could be an alternative treatment option in LMICs. Abstract THAB0104 presented at: AIDS; 2016 Jul 18\u201322; Durban, South Africa. New York: Wiley; 2016 [cited 2018 Apr 2] Available from https://onlinelibrary.wiley.com/doi/epdf/10.7448/IAS.19.6.21264."
                    },
                    {
                        "ref-fulltext": "Shah R, Ramjee G, Kityo C, et al. Safety and efficacy of TDF/FTC/RPV and TDF/FTC/ EFV \u2013 48 week subgroup-analyses from the SALIF study. Abstract 112 presented at: 11th INTEREST Workshop; 2017 May 16\u201319; Lilongwe, Malawi. Reviews in Antiviral Therapy & Infectious Diseases 2017_2. Amsterdam: Global Health and Development (AIGHD); 2017.",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Safety and efficacy of TDF/FTC/RPV and TDF/FTC/ EFV \u2013 48 week subgroup-analyses from the SALIF study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85072344392",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Abstract 112: May 16\u201319; Lilongwe, Malawi. Reviews in Antiviral Therapy & Infectious Diseases 2017_2. Amsterdam: Global Health and Development AIGHD",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Ramjee",
                                        "ce:indexed-name": "Ramjee G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Kityo",
                                        "ce:indexed-name": "Kityo C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "11th INTEREST Workshop; 2017"
                        },
                        "ce:source-text": "Shah R, Ramjee G, Kityo C, et al. Safety and efficacy of TDF/FTC/RPV and TDF/FTC/ EFV \u2013 48 week subgroup-analyses from the SALIF study. Abstract 112 presented at: 11th INTEREST Workshop; 2017 May 16\u201319; Lilongwe, Malawi. Reviews in Antiviral Therapy & Infectious Diseases 2017_2. Amsterdam: Global Health and Development (AIGHD); 2017."
                    },
                    {
                        "ref-fulltext": "Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191\u2013210. https://doi.org/10.1001/jama.2016.8900",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1001/jama.2016.8900",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84978371920",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "316",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "191",
                                    "@last": "210"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Günthard",
                                        "ce:indexed-name": "Gunthard H.F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Saag",
                                        "ce:indexed-name": "Saag M.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Benson",
                                        "ce:indexed-name": "Benson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA"
                        },
                        "ce:source-text": "Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191\u2013210. https://doi.org/10.1001/jama.2016.8900"
                    },
                    {
                        "ref-fulltext": "McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: A systematic review. Bull World Health Organ. 2013;91(5):377\u2012385E. https://doi.org/10.2471/BLT.12.112946",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.2471/BLT.12.112946",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Viral suppression after 12 months of antiretroviral therapy in low- And middle-income countries: A systematic review"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84877080156",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "pages": "377\u2012385E",
                                "voliss": {
                                    "@volume": "91",
                                    "@issue": "5"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.H.",
                                    "@_fa": "true",
                                    "ce:surname": "McMahon",
                                    "ce:indexed-name": "McMahon J.H."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.H.",
                                    "@_fa": "true",
                                    "ce:surname": "Elliott",
                                    "ce:indexed-name": "Elliott J.H."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Bertagnolio",
                                    "ce:indexed-name": "Bertagnolio S."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Kubiak",
                                    "ce:indexed-name": "Kubiak R."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "M.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Jordan",
                                    "ce:indexed-name": "Jordan M.R."
                                }
                            ]},
                            "ref-sourcetitle": "Bull World Health Organ"
                        },
                        "ce:source-text": "McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: A systematic review. Bull World Health Organ. 2013;91(5):377\u2012385E. https://doi.org/10.2471/BLT.12.112946"
                    },
                    {
                        "ref-fulltext": "Pinnetti C, Di Giambenedetto S, Maggiolo F, et al. Switching to coformulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. J Acquir Immune Defic Syndr. 2015;70(4):e147\u2013e150. https://doi.org/10.1097/QAI.0000000000000727",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAI.0000000000000727",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Switching to coformulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84945965589",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "70",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "e147",
                                    "@last": "e150"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Pinnetti",
                                        "ce:indexed-name": "Pinnetti C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Di Giambenedetto",
                                        "ce:indexed-name": "Di Giambenedetto S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Maggiolo",
                                        "ce:indexed-name": "Maggiolo F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Pinnetti C, Di Giambenedetto S, Maggiolo F, et al. Switching to coformulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. J Acquir Immune Defic Syndr. 2015;70(4):e147\u2013e150. https://doi.org/10.1097/QAI.0000000000000727"
                    },
                    {
                        "ref-fulltext": "Lewis JM, Smith C, Torkington A, et al. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study. J Infect. 2017;74(4):401\u2013407. https://doi.org/10.1016/j.jinf.2017.01.012",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.jinf.2017.01.012",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85011556487",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "74",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "401",
                                    "@last": "407"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Lewis",
                                        "ce:indexed-name": "Lewis J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Torkington",
                                        "ce:indexed-name": "Torkington A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Infect"
                        },
                        "ce:source-text": "Lewis JM, Smith C, Torkington A, et al. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study. J Infect. 2017;74(4):401\u2013407. https://doi.org/10.1016/j.jinf.2017.01.012"
                    },
                    {
                        "ref-fulltext": "Häggblom A, Lindbäck S, Gisslén M, et al. HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009\u20132014. PLoS One. 2017;12(2):e0171227. https://doi.org/10.1371/journal.pone.0171227",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1371/journal.pone.0171227",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009\u20132014"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "e0171227",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85012942155",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {
                                "@volume": "12",
                                "@issue": "2"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Häggblom",
                                        "ce:indexed-name": "Haggblom A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lindbäck",
                                        "ce:indexed-name": "Lindback S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gisslén",
                                        "ce:indexed-name": "Gisslen M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLoS One"
                        },
                        "ce:source-text": "Häggblom A, Lindbäck S, Gisslén M, et al. HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009\u20132014. PLoS One. 2017;12(2):e0171227. https://doi.org/10.1371/journal.pone.0171227"
                    },
                    {
                        "ref-fulltext": "Gianotti N, Maggiolo F, Cozzi-Lepri A, et al. Durability of RPV- and INSTI-based 1st-line regimens in HIV-infected patients starting ART with a VL <100 000 copies/mL: Data from the ICONA Foundation Study. Abstract MOPEB0300. Presented at: IAS; 2017 Jul 23\u201326; Paris, France. New York: Wiley; 2017.",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Durability of RPV- And INSTI-based 1st-line regimens in HIV-infected patients starting ART with a VL <100 000 copies/mL: Data from the Icona Foundation study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85072342867",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "IAS; Jul 23\u201326; Paris, France. New York: Wiley; 2017",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Gianotti",
                                        "ce:indexed-name": "Gianotti N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Maggiolo",
                                        "ce:indexed-name": "Maggiolo F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Cozzi-Lepri",
                                        "ce:indexed-name": "Cozzi-Lepri A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Abstract MOPEB0300"
                        },
                        "ce:source-text": "Gianotti N, Maggiolo F, Cozzi-Lepri A, et al. Durability of RPV- and INSTI-based 1st-line regimens in HIV-infected patients starting ART with a VL <100 000 copies/mL: Data from the ICONA Foundation Study. Abstract MOPEB0300. Presented at: IAS; 2017 Jul 23\u201326; Paris, France. New York: Wiley; 2017."
                    },
                    {
                        "ref-fulltext": "Sculier D, Gayet-Ageron A, Battegay M, et al. Rilpivirine use in the Swiss HIV cohort study: A prospective cohort study. BMC Infect Dis. 2017;17(1):476. https://doi.org/10.1186/s12879-017-2579-2",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1186/s12879-017-2579-2",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Rilpivirine use in the Swiss HIV cohort study: A prospective cohort study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85021959750",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "17",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "476"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Sculier",
                                        "ce:indexed-name": "Sculier D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Gayet-Ageron",
                                        "ce:indexed-name": "Gayet-Ageron A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Battegay",
                                        "ce:indexed-name": "Battegay M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BMC Infect Dis"
                        },
                        "ce:source-text": "Sculier D, Gayet-Ageron A, Battegay M, et al. Rilpivirine use in the Swiss HIV cohort study: A prospective cohort study. BMC Infect Dis. 2017;17(1):476. https://doi.org/10.1186/s12879-017-2579-2"
                    },
                    {
                        "ref-fulltext": "Raffi F, Orkin C, Clarke A, et al. Brief report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75(2):226\u2013231. https://doi.org/10.1097/QAI. 0000000000001344",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAI.0000000000001344",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Brief report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85014657477",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "75",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "226",
                                    "@last": "231"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Raffi",
                                        "ce:indexed-name": "Raffi F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Orkin",
                                        "ce:indexed-name": "Orkin C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Clarke",
                                        "ce:indexed-name": "Clarke A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Raffi F, Orkin C, Clarke A, et al. Brief report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75(2):226\u2013231. https://doi.org/10.1097/QAI. 0000000000001344"
                    },
                    {
                        "ref-fulltext": "Walensky RP, Horn TH, Paltiel AD. The epi-TAF for tenofovir disoproxil fumarate? Clin Infect Dis. 2016;62(7):915\u2013918. https://doi.org/10.1093/cid/ civ1000",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1093/cid/civ1000",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The epi-TAF for tenofovir disoproxil fumarate?"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84963958975",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "62",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "915",
                                    "@last": "918"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "R.P.",
                                    "@_fa": "true",
                                    "ce:surname": "Walensky",
                                    "ce:indexed-name": "Walensky R.P."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "T.H.",
                                    "@_fa": "true",
                                    "ce:surname": "Horn",
                                    "ce:indexed-name": "Horn T.H."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.D.",
                                    "@_fa": "true",
                                    "ce:surname": "Paltiel",
                                    "ce:indexed-name": "Paltiel A.D."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Walensky RP, Horn TH, Paltiel AD. The epi-TAF for tenofovir disoproxil fumarate? Clin Infect Dis. 2016;62(7):915\u2013918. https://doi.org/10.1093/cid/ civ1000"
                    },
                    {
                        "ref-fulltext": "Llibre JM, Hung CC, Brinson C, et al. Phase III SWORD 1&2: Switch to DTG+RPV maintains virologic suppression through 48 wks. Abstract 44LB. Presented at: Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13\u201316; Seattle, WA. Seattle, WA: CROI Foundation/IAS\u2013USA; 2017.",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Phase III Sword 1&2: Switch to DTG+RPV maintains virologic suppression through 48 wks"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85020681784",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "2017 Feb 13\u201316; Seattle, WA. Seattle, WA: CROI Foundation/IAS\u2013USA",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Llibre",
                                        "ce:indexed-name": "Llibre J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Hung",
                                        "ce:indexed-name": "Hung C.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Brinson",
                                        "ce:indexed-name": "Brinson C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Abstract 44LB. Presented at: Conference on Retroviruses and Opportunistic Infections"
                        },
                        "ce:source-text": "Llibre JM, Hung CC, Brinson C, et al. Phase III SWORD 1&2: Switch to DTG+RPV maintains virologic suppression through 48 wks. Abstract 44LB. Presented at: Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13\u201316; Seattle, WA. Seattle, WA: CROI Foundation/IAS\u2013USA; 2017."
                    },
                    {
                        "ref-fulltext": "World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition 9 June 2016. [cited 2019 Apr 2] Available from: http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf.",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {
                                "websitename": "World Health Organization",
                                "ce:e-address": {
                                    "$": "http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf",
                                    "@type": "email"
                                }
                            },
                            "ref-title": {"ref-titletext": "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84882279538",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Second edition 9 June cited 2019 Apr 2",
                            "ref-sourcetitle": "Recommendations for A Public Health Approach"
                        },
                        "ce:source-text": "World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition 9 June 2016. [cited 2019 Apr 2] Available from: http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf."
                    },
                    {
                        "ref-fulltext": "Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6):939\u2013950. https://doi.org/10.1097/QAD.0b013e32835cee6e",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAD.0b013e32835cee6e",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84876406278",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "939",
                                    "@last": "950"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Cassetti",
                                        "ce:indexed-name": "Cassetti I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6):939\u2013950. https://doi.org/10.1097/QAD.0b013e32835cee6e"
                    },
                    {
                        "ref-fulltext": "Ford N, Shubber Z, Pozniak A, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: A systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69(4):422\u2012429. https://doi.org/10.1097/QAI.0000000000000606",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/QAI.0000000000000606",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: A systematic review and meta-analysis of randomized trials"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84941767863",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "69",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "422",
                                    "@last": "429"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Ford",
                                        "ce:indexed-name": "Ford N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Shubber",
                                        "ce:indexed-name": "Shubber Z."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Pozniak",
                                        "ce:indexed-name": "Pozniak A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Ford N, Shubber Z, Pozniak A, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: A systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69(4):422\u2012429. https://doi.org/10.1097/QAI.0000000000000606"
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Johannesburg",
            "@id": "60016218",
            "affilname": "University of the Witwatersrand, Johannesburg",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016218",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "London",
            "@id": "60015879",
            "affilname": "Medical Research Council",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015879",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Douala",
            "@id": "123178620",
            "affilname": "Cabinet Medical IDOC",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178620",
            "affiliation-country": "Cameroon"
        },
        {
            "affiliation-city": null,
            "@id": "123178472",
            "affilname": "Partners in Prevention",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178472",
            "affiliation-country": "Kenya"
        },
        {
            "affiliation-city": "Dakar",
            "@id": "123178306",
            "affilname": "Centre de Santé Gaspard KAMARA",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178306",
            "affiliation-country": "Senegal"
        },
        {
            "affiliation-city": "Antwerpen",
            "@id": "120331258",
            "affilname": "BICER Consulting &amp; Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/120331258",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Breda",
            "@id": "118601347",
            "affilname": "Janssen-Cilag BV",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/118601347",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "High Wycombe",
            "@id": "113734673",
            "affilname": "Janssen",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113734673",
            "affiliation-country": "United Kingdom"
        }
    ],
    "coredata": {
        "srctype": "j",
        "prism:issueIdentifier": "1",
        "eid": "2-s2.0-85072338061",
        "dc:description": "Background: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Objectives: Switching at Low HIV-1 RNA into Fixed Dose Combinations (SALIF) compared RPV with efavirenz (EFV), both as STRs with TDF and FTC, in maintaining virologic suppression. Methods: SALIF was a phase 3b, randomised, open-label, non-inferiority study in virologically suppressed adults (HIV-1 RNA < 50 copies/mL) on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) in Cameroon, Kenya, Senegal, South Africa, Uganda and Thailand. Patients (N = 426), stratified by NNRTI use, were randomised 1:1 to receive TDF/FTC/RPV (300/200/25 mg qd) or TDF/FTC/EFV (300/200/600 mg qd). Primary endpoint was proportion of patients with virologic suppression (HIV-1 RNA < 400 copies/mL) at week 48 (intent-to-treat, modified Food and Drug Administration Snapshot, 10% non-inferiority margin). Results: Patients received TDF/FTC/RPV (n = 213) or TDF/FTC/EFV (n = 211). At week 48, virologic suppression was maintained in 200/213 (93.9%) patients in the RPV arm and 203/211 (96.2%) in the EFV arm (difference \u20132.3%; 95% confidence interval: -6.4, +1.8), demonstrating non-inferiority of TDF/FTC/RPV. One patient in each arm experienced virologic failure without treatment-emergent resistance. Twenty-seven patients discontinued prematurely (8.0% RPV vs. 4.7% EFV), the most frequent reasons being adverse events (3.3% vs. 0.5%, respectively), site closure (1.9% vs. 0.5%), loss to follow-up (0.9% vs. 1.4%) and consent withdrawal (0.9% vs. 1.4%). Conclusion: In adults with suppressed viral load on first-line NNRTI-based ART in LMICs, switching to an STR of TDF/FTC/RPV was non-inferior to TDF/FTC/EFV in maintaining high rates of viral suppression with a comparable tolerability profile.",
        "prism:coverDate": "2019-07-23",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85072338061",
        "subtypeDescription": "Article",
        "dc:creator": {"author": [{
            "ce:given-name": "Paula",
            "preferred-name": {
                "ce:given-name": "Paula",
                "ce:initials": "P.",
                "ce:surname": "Munderi",
                "ce:indexed-name": "Munderi P."
            },
            "@seq": "1",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60015879",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015879"
            },
            "ce:surname": "Munderi",
            "@auid": "57191037895",
            "author-url": "https://api.elsevier.com/content/author/author_id/57191037895",
            "ce:indexed-name": "Munderi P."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85072338061"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072338061&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85072338061&origin=inward"
            }
        ],
        "prism:publicationName": "Southern African Journal of HIV Medicine",
        "source-id": "93433",
        "citedby-count": "3",
        "prism:volume": "20",
        "subtype": "ar",
        "dc:title": "Switching at low HIV-1 RNA into fixed dose combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/ EFV in first-line suppressed patients living with HIV",
        "openaccess": "1",
        "openaccessFlag": "true",
        "prism:doi": "10.4102/sajhivmed.v20i1.949",
        "prism:issn": "20786751 16089693",
        "publishercopyright": "© 2019. The Authors.",
        "article-number": "a949",
        "dc:identifier": "SCOPUS_ID:85072338061",
        "dc:publisher": "AOSIS (pty) Ltdpublishing@aosis.co.za"
    },
    "idxterms": null,
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "LMIC"
        },
        {
            "@_fa": "true",
            "$": "SALIF"
        },
        {
            "@_fa": "true",
            "$": "Single-Tablet-Regimen"
        },
        {
            "@_fa": "true",
            "$": "Treatment-emergent Resistance"
        },
        {
            "@_fa": "true",
            "$": "Virologically suppressed adults"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Infectious Diseases",
        "@code": "2725",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Paula",
            "preferred-name": {
                "ce:given-name": "Paula",
                "ce:initials": "P.",
                "ce:surname": "Munderi",
                "ce:indexed-name": "Munderi P."
            },
            "@seq": "1",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60015879",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015879"
            },
            "ce:surname": "Munderi",
            "@auid": "57191037895",
            "author-url": "https://api.elsevier.com/content/author/author_id/57191037895",
            "ce:indexed-name": "Munderi P."
        },
        {
            "ce:given-name": "Edwin",
            "preferred-name": {
                "ce:given-name": "Edwin",
                "ce:initials": "E.",
                "ce:surname": "Were",
                "ce:indexed-name": "Were E."
            },
            "@seq": "2",
            "ce:initials": "E.",
            "@_fa": "true",
            "affiliation": {
                "@id": "123178472",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178472"
            },
            "ce:surname": "Were",
            "@auid": "6603179809",
            "author-url": "https://api.elsevier.com/content/author/author_id/6603179809",
            "ce:indexed-name": "Were E."
        },
        {
            "ce:given-name": "Anchalee",
            "preferred-name": {
                "ce:given-name": "Anchalee",
                "ce:initials": "A.",
                "ce:surname": "Avihingsanon",
                "ce:indexed-name": "Avihingsanon A."
            },
            "@seq": "3",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60016965",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"
                },
                {
                    "@id": "60028190",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
                }
            ],
            "ce:surname": "Avihingsanon",
            "@auid": "57196347321",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196347321",
            "ce:indexed-name": "Avihingsanon A."
        },
        {
            "ce:given-name": "Pascale A.M.",
            "preferred-name": {
                "ce:given-name": "Pascale A.M.",
                "ce:initials": "P.A.M.",
                "ce:surname": "Mbida",
                "ce:indexed-name": "Mbida P.A.M."
            },
            "@seq": "4",
            "ce:initials": "P.A.M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "123178620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178620"
            },
            "ce:surname": "Mbida",
            "@auid": "57211033214",
            "author-url": "https://api.elsevier.com/content/author/author_id/57211033214",
            "ce:indexed-name": "Mbida P.A.M."
        },
        {
            "ce:given-name": "Lerato",
            "preferred-name": {
                "ce:given-name": "Lerato",
                "ce:initials": "L.",
                "ce:surname": "Mohapi",
                "ce:indexed-name": "Mohapi L."
            },
            "@seq": "5",
            "ce:initials": "L.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60016218",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016218"
            },
            "ce:surname": "Mohapi",
            "@auid": "24734526800",
            "author-url": "https://api.elsevier.com/content/author/author_id/24734526800",
            "ce:indexed-name": "Mohapi L."
        },
        {
            "ce:given-name": "Samba B.",
            "preferred-name": {
                "ce:given-name": "Samba B.",
                "ce:initials": "S.B.",
                "ce:surname": "Moussa",
                "ce:indexed-name": "Moussa S.B."
            },
            "@seq": "6",
            "ce:initials": "S.B.",
            "@_fa": "true",
            "affiliation": {
                "@id": "123178306",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178306"
            },
            "ce:surname": "Moussa",
            "@auid": "57211032927",
            "author-url": "https://api.elsevier.com/content/author/author_id/57211032927",
            "ce:indexed-name": "Moussa S.B."
        },
        {
            "ce:given-name": "Marjolein",
            "preferred-name": {
                "ce:given-name": "Marjolein",
                "ce:initials": "M.",
                "ce:surname": "Jansen",
                "ce:indexed-name": "Jansen M."
            },
            "@seq": "7",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "118601347",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/118601347"
            },
            "ce:surname": "Jansen",
            "@auid": "57211029130",
            "author-url": "https://api.elsevier.com/content/author/author_id/57211029130",
            "ce:indexed-name": "Jansen M."
        },
        {
            "ce:given-name": "Ceyhun",
            "preferred-name": {
                "ce:given-name": "Ceyhun",
                "ce:initials": "C.",
                "ce:surname": "Bicer",
                "ce:indexed-name": "Bicer C."
            },
            "@seq": "8",
            "ce:initials": "C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "120331258",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/120331258"
            },
            "ce:surname": "Bicer",
            "@auid": "57192910993",
            "author-url": "https://api.elsevier.com/content/author/author_id/57192910993",
            "ce:indexed-name": "Bicer C."
        },
        {
            "ce:given-name": "Perry",
            "preferred-name": {
                "ce:given-name": "Perry",
                "ce:initials": "P.",
                "ce:surname": "Mohammed",
                "ce:indexed-name": "Mohammed P."
            },
            "@seq": "9",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "113734673",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113734673"
            },
            "ce:surname": "Mohammed",
            "@auid": "53871783200",
            "author-url": "https://api.elsevier.com/content/author/author_id/53871783200",
            "ce:indexed-name": "Mohammed P."
        },
        {
            "ce:given-name": "Yvon",
            "preferred-name": {
                "ce:given-name": "Yvon",
                "ce:initials": "Y.",
                "ce:surname": "van Delft",
                "ce:indexed-name": "van Delft Y."
            },
            "@seq": "10",
            "ce:initials": "Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "118601347",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/118601347"
            },
            "ce:surname": "van Delft",
            "@auid": "35410941100",
            "author-url": "https://api.elsevier.com/content/author/author_id/35410941100",
            "ce:indexed-name": "van Delft Y."
        }
    ]}
}}